Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing Partners fo

KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC (http://www.numodacapital.com) to license its TruPoints® strategic partnering platform.

Provectus will use Numoda’s TruPoints to facilitate transactions with potential licensing partners for PH-10, its therapy for the treatment of serious dermatological diseases, which recently showed positive Phase 2 clinical trial results in both Atopic Dermatitis and Psoriasis. The TruPoints platform will organize all due diligence material relating to the Phase 2 clinical trials, including business, scientific and contract manufacturing information and has the unique ability to include appropriate live trial information. All of this is expected to significantly facilitate the flow of information to potential licensees. Numoda’s TruPoints platform has a strong track record of helping numerous development stage biotech companies secure big pharma licensing agreements.

Craig Dees, Ph.D., CEO of Provectus said, “As we actively seek to out-license PH-10, Numoda TruPoints will enable the exchange of scientific and business information between Provectus and potential partners. We expect this platform to play a critical role in the out-licensing process when we formally engage an investment banker.”

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cancer. The Company has received orphan drug designation from the FDA for its melanoma indication. Its lead dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed enrollment in three Phase 2 trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and for psoriasis. It has also recently initiated a Phase 1 trial of PV-10 for liver cancer. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.



CONTACT:

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO, 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP – Investor Relations
Bill Gordon, SVP – Media Relations
212-564-4700

KEYWORDS:   United States  North America  Tennessee

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.